Biotech Acquisition Company Warrant
BIOTW
BIOTW was delisted on the 2nd of February, 2023.
56 hedge funds and large institutions have $8.44M invested in Biotech Acquisition Company Warrant in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 4 closing their positions.
425% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 4
44% more funds holding
Funds holding: 39 → 56 (+17)
30% more capital invested
Capital invested by funds: $6.51M → $8.44M (+$1.93M)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$736K |
| 2 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$382K |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$153K |
| 4 |
QGA
Q Global Advisors
Fort Worth,
Texas
|
+$87.3K |
| 5 |
AC
Antara Capital
New York
|
+$76.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DG Capital Management
New York
|
-$148K |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
-$127K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$122K |
| 4 |
RA
Ramius Advisors
New York
|
-$119K |
| 5 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$111K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
51
HRT Financial
New York
| $12K | +$13.4K | +19,351 | New |
|
|
BCM
52
Basso Capital Management
Stamford,
Connecticut
| $8K | – | – | – |
|
|
OAC
53
OMERS Administration Corp
Toronto,
Ontario, Canada
| $8K | – | – | – |
|
54
Bank of America
Charlotte,
North Carolina
| $7K | – | – | – |
|
|
MIG
55
Mariner Investment Group
Harrison,
New York
| $7K | +$6.94K | +10,000 | New |
|
|
AA
56
Ancora Advisors
Cleveland,
Ohio
| $4K | – | – | – |
|
57
UBS Group
Zurich,
Switzerland
| $2K | +$1.85K | +2,674 | New |
|
|
DCM
58
DG Capital Management
New York
| – | -$148K | -224,999 | Closed |
|
|
59
Nomura Holdings
Tokyo,
Japan
| – | -$127K | -200,000 | Closed |
|
|
PMAM
60
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
| – | -$51K | -75,000 | Closed |
|
|
EAM
61
Exos Asset Management
New York
| – | -$8K | -12,407 | Closed |
|
BIOTW Hedge Fund Activity: Q4 2021 in Review
56 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q4 2021, worth a combined $8.44M — up 30% from $6.51M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new BIOTW positions and 4 closed out — a net gain of 17 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Aristeia Capital, opening a new position worth an estimated $736K. The largest seller was DG Capital Management, exiting entirely with an estimated $148K sold.
- 56 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q4 2021, up from 39 in Q3 2021.
- Funds reported $8.44M of Biotech Acquisition Company Warrant stock for Q4 2021, up 30% quarter-over-quarter.
- 21 funds opened new Biotech Acquisition Company Warrant positions in Q4 2021 and 4 closed out, a net change of +17 holders.
- The largest Biotech Acquisition Company Warrant buyer in Q4 2021 was Aristeia Capital, an estimated $736K added.
- The largest Biotech Acquisition Company Warrant seller in Q4 2021 was DG Capital Management, an estimated $148K sold.
Based on aggregated 13F filings for Q4 2021.